Joseph M. Limber Buys 5,243 Shares of XOMA Co. (NASDAQ:XOMA) Stock

XOMA Co. (NASDAQ:XOMA) Director Joseph M. Limber acquired 5,243 shares of the business’s stock in a transaction that occurred on Monday, April 7th. The shares were bought at an average price of $25.60 per share, with a total value of $134,220.80. Following the completion of the purchase, the director now owns 10,000 shares in the company, valued at $256,000. This trade represents a 110.22 % increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

XOMA Stock Up 7.6 %

NASDAQ XOMA opened at $20.19 on Thursday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 7.52 and a current ratio of 7.52. The company has a market capitalization of $241.86 million, a P/E ratio of -5.80 and a beta of 1.00. XOMA Co. has a one year low of $18.35 and a one year high of $35.00. The stock has a 50 day moving average price of $22.36 and a 200-day moving average price of $26.30.

XOMA (NASDAQ:XOMA) last released its quarterly earnings results on Monday, March 17th. The biotechnology company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.29) by ($0.17). XOMA had a negative net margin of 151.34% and a negative return on equity of 24.95%. The company had revenue of $8.70 million for the quarter, compared to analysts’ expectations of $8.75 million. As a group, equities analysts predict that XOMA Co. will post -1.41 EPS for the current fiscal year.

Institutional Trading of XOMA

Several hedge funds and other institutional investors have recently bought and sold shares of XOMA. Geode Capital Management LLC increased its stake in XOMA by 0.6% in the third quarter. Geode Capital Management LLC now owns 182,741 shares of the biotechnology company’s stock worth $4,840,000 after purchasing an additional 1,138 shares during the period. Barclays PLC increased its stake in XOMA by 300.7% in the third quarter. Barclays PLC now owns 11,256 shares of the biotechnology company’s stock worth $298,000 after purchasing an additional 8,447 shares during the period. BNP Paribas Financial Markets increased its stake in XOMA by 95.0% in the third quarter. BNP Paribas Financial Markets now owns 1,632 shares of the biotechnology company’s stock worth $43,000 after purchasing an additional 795 shares during the period. State Street Corp increased its stake in XOMA by 1.2% in the third quarter. State Street Corp now owns 142,857 shares of the biotechnology company’s stock worth $3,783,000 after purchasing an additional 1,754 shares during the period. Finally, New York State Common Retirement Fund increased its stake in XOMA by 51.2% in the fourth quarter. New York State Common Retirement Fund now owns 2,362 shares of the biotechnology company’s stock worth $62,000 after purchasing an additional 800 shares during the period. Hedge funds and other institutional investors own 95.92% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and set a $104.00 price objective on shares of XOMA in a research note on Friday, March 28th. StockNews.com downgraded XOMA from a “hold” rating to a “sell” rating in a research note on Thursday, April 3rd.

About XOMA

XOMA Corporation operates as a biotech royalty aggregator in the United States and the Asia Pacific. It has a portfolio of economic rights to future potential milestone and royalty payments associated with partnered commercial and pre-commercial therapeutic candidates. The company also focuses on early to mid-stage clinical assets primarily in Phase 1 and 2 with commercial sales potential that are licensed to partners; and acquires milestone and royalty revenue streams on late-stage clinical or commercial assets.